These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 32575026)

  • 1. The relationship between aquaporin-4 antibody status and visual tract integrity in neuromyelitis optica spectrum disorders: A visual evoked potential study.
    Barć K; Gospodarczyk-Szot K; Nojszewska M; Podlecka-Piętowska A; Zakrzewska-Pniewska B
    Mult Scler Relat Disord; 2020 Sep; 44():102265. PubMed ID: 32575026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The absence of antibodies in longitudinally extensive transverse myelitis may predict a more favourable prognosis.
    Rocchi C; Forcadela M; Kelly P; Linaker S; Gibbons E; Bhojak M; Jacob A; Hamid S; Huda S
    Mult Scler; 2024 Mar; 30(3):345-356. PubMed ID: 38258822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Newly diagnosed neuromyelitis optica spectrum disorders following vaccination: Case report and systematic review.
    Anamnart C; Tisavipat N; Owattanapanich W; Apiwattanakul M; Savangned P; Prayoonwiwat N; Siritho S; Rattanathamsakul N; Jitprapaikulsan J
    Mult Scler Relat Disord; 2022 Feb; 58():103414. PubMed ID: 35216789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of serostatus in pediatric neuromyelitis optica spectrum disorders: A nationwide multicentric study.
    Solmaz I; Öncel IH; Konuşkan B; Erol I; Orgun LT; Yılmaz Ü; Ünalp A; Atasoy E; Aksoy E; Yılmaz D; Öztürk M; Karaca NB; Yılmaz S; Yiş U; Dündar NO; Parlak Ş; Vural A; Günbey C; Anlar B
    Mult Scler Relat Disord; 2023 Sep; 77():104847. PubMed ID: 37393803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum Biomarker Profiles Discriminate AQP4 Seropositive and Double Seronegative Neuromyelitis Optica Spectrum Disorder.
    Carta S; Dinoto A; Capobianco M; Valentino P; Montarolo F; Sala A; Reindl M; Lo Re M; Chiodega V; Branger P; Audoin B; Aboab J; Papeix C; Collongues N; Kerschen P; Zephir H; Créange A; Bourre B; Schanda K; Flanagan EP; Redenbaugh V; Villacieros-Álvarez J; Arrambide G; Cobo-Calvo A; Ferrari S; Marignier R; Mariotto S
    Neurol Neuroimmunol Neuroinflamm; 2024 Jan; 11(1):e200188. PubMed ID: 38134369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overlap syndrome of anti-aquaporin-4 positive neuromyelitis optica spectrum disorder and systemic lupus erythematosus: A systematic review of individual patient data.
    Kopp CR; Prasad CB; Naidu S; Sharma V; Misra DP; Agarwal V; Sharma A
    Lupus; 2023 Sep; 32(10):1164-1172. PubMed ID: 37487596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Visual Evoked Potentials in Patients Affected by Optic Neuritis From Multiple Sclerosis or Neuromyelitis Optica Spectrum Disorder.
    Filgueiras TG; Oyamada MK; Hokazono K; Cunha LP; Apóstolos-Pereira SL; Callegaro D; Monteiro MLR
    J Neuroophthalmol; 2022 Mar; 42(1):e32-e39. PubMed ID: 34348361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aquaporin-4-IgG positive neuromyelitis optica spectrum disorder in a paraneoplastic context.
    Hyun JW; Park NY; Kim MJ; Kim H; Kim KH; Kim SH; Kim HJ
    J Neurol Sci; 2023 Nov; 454():120825. PubMed ID: 37813018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and demographic characteristics of patients with NMOSD: a longitudinal retrospective analysis of a Slovak cohort of 63 patients.
    Szilasiová J; Gazda J; Mikula P; Cvengrošová A; Fedičová M; Hančinová V; Kantorová E; Karlík M; Kováčová S
    Neurol Sci; 2024 Feb; 45(2):693-698. PubMed ID: 37698786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuromyelitis optica spectrum disorder: do patients positive and negative for anti-aquaporin-4 antibodies present distinct entities? A Colombian perspective.
    Ortiz Salas PA; Gaviria Carrillo M; Cortés Bernal GA; Moreno Medina K; Roa LF; Rodríguez Quintana JH
    Neurologia (Engl Ed); 2023 Sep; 38(7):504-510. PubMed ID: 35637138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between severe attacks and serum aquaporin-4 antibody titer in neuromyelitis optica spectrum disorder.
    Wang R; Sun D; Wang X; Shi Z; Kong L; Du Q; Zhang Y; Chen H; Luo W; Zhang N; Zhou H
    J Neurol; 2024 Jul; 271(7):4503-4512. PubMed ID: 38703259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in the long-term treatment of neuromyelitis optica spectrum disorder.
    Anderson M; Levy M
    J Cent Nerv Syst Dis; 2024; 16():11795735241231094. PubMed ID: 38312734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aquaporin-4 autoantibodies in neuromyelitis optica spectrum disorders: comparison between tissue-based and cell-based indirect immunofluorescence assays.
    Chan KH; Kwan JS; Ho PW; Ho JW; Chu AC; Ramsden DB
    J Neuroinflammation; 2010 Sep; 7():50. PubMed ID: 20822515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 2015 IPND Criteria Increases the Yield in Diagnosis of Neuromyelitis Optica Spectrum Disorder in Thai Patients Compared to the 2006 Diagnostic Criteria.
    Rattanathamsakul N; Kaveeta C; Siritho S; Thakolwiboon S; Prayoonwiwat N
    Mult Scler Relat Disord; 2020 Aug; 43():102218. PubMed ID: 32474289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different clinical phenotypes of AQP4-IgG positive NMOSD in two first degree relatives.
    Ssemmanda S; Musubire AK
    BMC Neurol; 2023 Sep; 23(1):315. PubMed ID: 37667215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuromyelitis Optica spectrum disorders in Argentina: A hospital-based study.
    Villa AM; Manin A; Seimandi C; Finkelsteyn AM; Ramos G; Tenembaum S
    Mult Scler Relat Disord; 2023 Nov; 79():105018. PubMed ID: 37806234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retinal Changes in Double-Antibody Seronegative Neuromyelitis Optica Spectrum Disorders.
    Oertel FC; Zimmermann HG; Motamedi S; Bereuter C; Manthey LM; Ashtari F; Kafieh R; Dehghani A; Pourazizi M; Pandit L; D'Cunha A; Aktas O; Albrecht P; Ringelstein M; Martinez-Lapiscina EH; Sanchez Dalmau BF; Villoslada P; Asgari N; Marignier R; Cobo-Calvo A; Leocani L; Pisa M; Radaelli M; Palace J; Roca-Fernandez A; Leite MIS; Sharma S; De Seze J; Senger T; Yeaman MR; Smith TJ; Cook LJ; Brandt AU; Paul F;
    Neurol Neuroimmunol Neuroinflamm; 2024 Sep; 11(5):e200273. PubMed ID: 38941573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiologic and clinical characteristics of neuromyelitis optica spectrum disorder patients, A seven years follow-up study from Iran.
    Ashtari F; Mehdipour R; Eini A; Ghalamkari A
    Mult Scler Relat Disord; 2023 Sep; 77():104852. PubMed ID: 37399672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double Seronegative Neuromyelitis Optica Spectrum Disorder with Longitudinally Extensive Transverse Myelitis and Optic Neuritis: A Challenging Case Report.
    Chon Han G; Iqbal T; Supramaniam G
    Cureus; 2024 Mar; 16(3):e57044. PubMed ID: 38681400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum antinuclear antibodies associate with severe disease activity in neuromyelitis optica spectrum disorder.
    Wang R; Sun DR; Du Q; Zhang Y; Chen HX; Wang XF; Kong LY; Luo WQ; Shi ZY; Zhou HY
    J Neuroimmunol; 2023 Sep; 382():578151. PubMed ID: 37453208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.